Polyneuritis refers to inflammation or damage affecting multiple peripheral nerves at the same time, producing a mix of numbness, tingling, pain, and muscle weakness that typically starts in the feet and hands before spreading inward. The condition has dozens of possible triggers, from autoimmune attacks and infections to nutritional shortfalls, toxic exposures, and chronic diseases like diabetes. Because the underlying cause shapes nearly everything about how the disease behaves and how it responds to treatment, pinpointing the reason behind the nerve damage is just as important as managing symptoms.
What Happens Inside the Nerves
Peripheral nerves are long cables that relay signals between the brain, spinal cord, and the rest of the body. Each nerve fiber is wrapped in a fatty insulating layer called myelin, which speeds electrical signals along the fiber the way rubber coating insulates a wire. Polyneuritis can damage the myelin sheath (demyelination), the nerve fiber itself (axonal damage), or both. Which type of damage predominates matters a great deal: demyelinating forms tend to come on faster and often respond well to immune-targeted therapy, while axonal forms may progress more slowly but can be harder to reverse.
Researchers can now distinguish these two patterns with increasing precision. Advanced MRI techniques, for example, show that hereditary demyelinating neuropathies produce measurably different nerve-tissue signatures than axonal neuropathies, with demyelinating disease showing greater swelling of the nerve’s fluid compartment while axonal disease shows different signal changes on imaging.1PubMed Central. Multiparametric Quantitative MRI of Peripheral Nerves to Differentiate Demyelinating from Axonal Polyneuropathies Nerve biopsy and pathology studies further confirm that even conditions that look similar on the surface can involve quite different underlying mechanisms. Chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, for instance, both cause motor weakness and both involve the immune system, yet biopsy evidence points to chronic demyelination in one and a targeted immune attack on motor nerve connections in the other.2PubMed. Nerve Pathology Distinguishes Focal Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Multifocal Motor Neuropathy
Autoimmune and Inflammatory Causes
The immune system is one of the most common culprits behind polyneuritis. In Guillain-Barré syndrome (GBS), the best-known acute form, a preceding infection triggers the body to produce antibodies that cross-react with components of peripheral nerves. This process, called molecular mimicry, is triggered by at least five distinct common bacterial and viral pathogens, making GBS a genuinely polymicrobial disease.3PubMed Central. Guillain-Barré syndrome: expanding the concept of molecular mimicry The antibodies target gangliosides, fatty sugar molecules concentrated on nerve surfaces. GBS is considered the strongest proven example of molecular mimicry driving autoimmune disease in humans.4Trends in Immunology. Guillain-Barré syndrome: expanding the concept of molecular mimicry Emerging infections have joined the list of known triggers: both Zika virus and COVID-19 have been linked to GBS, with most post-infection cases showing the acute inflammatory demyelinating pattern.5PubMed Central. Emerging Infection, Vaccination, and Guillain-Barré Syndrome: A Review
CIDP is essentially the chronic cousin of GBS. Rather than hitting fast and burning out over weeks, CIDP develops over months or follows a relapsing course. The exact mechanisms are still debated, but both B cells and T cells seem to play a role.6PubMed Central. Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins In a small but important subset of CIDP patients, researchers have identified specific autoantibodies that target proteins at the nodes of Ranvier, the tiny gaps between myelin segments where electrical signals jump from one segment to the next. About 30% of CIDP patients have antibodies that bind to these nodal or paranodal regions, with targets including neurofascin, contactin-1, and gliomedin.7Journal of Neurology, Neurosurgery & Psychiatry. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype These antibodies do not all behave the same way: lab experiments show that anti-neurofascin-155 antibodies can bind strongly to nodal structures and produce sensorimotor neuropathy in animal models, while anti-contactin-1 antibodies bind weakly and produce no visible disease in the same models.8PubMed Central. Different binding and pathogenic effect of neurofascin and contactin-1 autoantibodies in autoimmune nodopathies This kind of granularity is why neurologists increasingly think of CIDP not as a single disease but as a family of related conditions that may eventually require different treatments.
Vasculitis, or inflammation of the blood vessels that supply nerves, is another immune-related cause worth knowing about. It can affect peripheral nerves on its own, as an isolated condition, or it can show up as part of a body-wide inflammatory disease.9PubMed Central. Diagnosis and therapeutic options for peripheral vasculitic neuropathy When blood supply to a nerve is cut off, the nerve fiber dies in patchy segments, which is why vasculitic neuropathy often affects different nerves asymmetrically rather than causing the even, stocking-glove pattern more typical of other forms of polyneuritis.
Toxic, Metabolic, and Nutritional Causes
Diabetes is the most common metabolic cause of polyneuropathy worldwide. Chronically elevated blood sugar damages small blood vessels supplying nerves and directly harms nerve fibers through several biochemical pathways. The resulting neuropathy usually starts as burning, tingling, or numbness in the feet and creeps upward over years.
Chemotherapy is a major toxic cause. Several classes of cancer drugs damage peripheral nerves, but they do so through different mechanisms, which means chemotherapy-induced polyneuropathy is not a single uniform entity. Platinum-based drugs, taxanes, vinca alkaloids, and proteasome inhibitors each damage nerves in their own way.10PubMed Central. Chemotherapy-induced polyneuropathy. Part I. Pathophysiology Sensory symptoms such as numbness and pain predominate in most drug classes, though some agents can also cause motor weakness.11PubMed Central. Chemotherapy-induced peripheral neuropathy: A current review The severity often depends on cumulative dose, and symptoms sometimes worsen for weeks after chemotherapy ends, a phenomenon oncologists call “coasting.” In many cases, once the drug is stopped, slow recovery begins, but some patients are left with permanent sensory deficits.
Alcohol deserves mention as a toxic cause as well. Heavy long-term drinking damages nerves both directly and through the nutritional deficiencies it creates, particularly thiamine (vitamin B1) deficiency. Speaking of thiamine, its absence alone can cause polyneuropathy identical to classic beriberi neuropathy. Research comparing patients who developed neuropathy after stomach surgery (which impairs thiamine absorption) with patients who had dietary beriberi found the two conditions to be clinically and pathologically identical.12PubMed. Postgastrectomy polyneuropathy with thiamine deficiency is identical to beriberi neuropathy Other B vitamins, particularly B6 and B12, are also essential for nerve health, and deficiencies in either can produce or worsen polyneuropathy.
Direct infections can also damage peripheral nerves. HIV, hepatitis C, Lyme disease, leprosy, and several parasitic infections are known to involve the peripheral nervous system. Some of these infections damage nerves directly, while others trigger an immune response that does the damage indirectly.13PubMed Central. Peripheral nervous system manifestations of infectious diseases Complicating matters, some of the antimicrobial drugs used to treat these infections can themselves cause neuropathy as a side effect.
Recognizing the Symptoms
The symptoms of polyneuritis depend on which types of nerve fibers are affected. Peripheral nerves carry three kinds of signals: sensory (touch, pain, temperature, vibration), motor (commands to muscles), and autonomic (automatic control of things like heart rate, blood pressure, digestion, and sweating). Polyneuritis can involve any combination of these.
Sensory symptoms are the most common first sign. Numbness, tingling, and a “pins and needles” sensation typically begin in the toes or feet and gradually move upward. Neuropathic pain, which can feel like burning, stabbing, or an electric shock, is common and sometimes severe. Motor involvement shows up as muscle weakness, cramps, and eventually muscle wasting if nerve damage progresses. Autonomic symptoms are often overlooked but can be disabling: they include drops in blood pressure when standing, digestive problems like constipation or bloating, abnormal sweating, and sexual dysfunction.14PubMed Central. Diagnosis and management of patients with polyneuropathy
The pattern of symptoms offers diagnostic clues. A symmetrical, length-dependent pattern (worst in the feet and hands, spreading inward) suggests metabolic or toxic causes like diabetes or chemotherapy. An asymmetric or patchy pattern, where one limb is hit harder than others, points toward vasculitis or multifocal motor neuropathy. Rapid onset over days suggests GBS, while gradual onset over months or years is more typical of CIDP, diabetic neuropathy, or hereditary forms.
How Polyneuritis Is Diagnosed
Diagnosis starts with a careful clinical history and neurological exam. A doctor will check your reflexes, assess muscle strength, and test your ability to feel light touch, pinprick, vibration, and temperature. The pattern of findings on exam narrows the list of possible causes considerably.
Nerve conduction studies and electromyography (often bundled together as “EMG/NCS”) are the standard next step. Nerve conduction studies measure how quickly and strongly electrical signals travel along a nerve. Slow conduction velocities point to demyelination; reduced signal strength with normal speed points to axonal damage. Electromyography checks for abnormal electrical activity in muscles, which can reveal ongoing nerve damage or early re-innervation as nerves try to recover.
Blood work is essential for identifying the underlying cause. Standard panels typically include fasting blood glucose or hemoglobin A1c (for diabetes), vitamin B12 and folate levels, thyroid function, kidney and liver function, inflammatory markers, and screening for common autoimmune antibodies. Depending on the clinical picture, additional tests may be ordered for specific toxins, heavy metals, HIV, hepatitis, Lyme antibodies, or paraprotein disorders.
Cerebrospinal fluid (CSF) analysis is sometimes needed, particularly when an inflammatory or demyelinating condition is suspected. Elevated protein in the CSF is a hallmark of GBS and CIDP, though it is not specific to those conditions. Newer research is exploring whether CSF sphingomyelin could serve as a more precise biomarker that distinguishes active demyelination from simple inflammation, since sphingomyelin levels in CSF did not correlate with general markers of inflammation like protein concentration or immunoglobulin levels.15Journal of Neurology, Neurosurgery & Psychiatry. CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS If validated in larger studies, this kind of biomarker could help clinicians catch demyelinating disease earlier and monitor treatment response more accurately.
Nerve biopsy and skin biopsy occupy a smaller but important role. Nerve biopsy (usually of the sural nerve in the ankle) is reserved for cases where the diagnosis remains uncertain after less invasive tests, particularly when vasculitis or amyloidosis is suspected. Skin punch biopsy is increasingly used to count intra-epidermal nerve fiber density, which helps diagnose small-fiber neuropathy, a form that often escapes detection by standard nerve conduction studies because it affects the very smallest sensory fibers.
Treating the Underlying Cause
Treatment strategy hinges on what is driving the nerve damage. When a treatable cause can be identified and addressed, the neuropathy may stabilize or even improve.
For immune-mediated polyneuropathies, the goal is to dampen the immune attack. In GBS, two treatments have strong evidence behind them: plasma exchange (where blood is filtered to remove harmful antibodies) and intravenous immunoglobulin (IVIg, which floods the system with donated antibodies that appear to modulate the immune response). A Cochrane review established plasma exchange as the first treatment proven superior to supportive care alone in GBS.16PubMed. Plasma exchange for Guillain-Barré syndrome A later meta-analysis comparing the two found no significant difference in disability improvement between plasma exchange and IVIg for patients with severe GBS, with identical odds of achieving at least one grade of improvement on standard disability scales.17PubMed Central. Plasma exchange versus intravenous immunoglobulin for the treatment of Guillain-Barré syndrome in patients with severe symptoms: A systematic review and meta-analysis In practice, the choice between them often depends on local availability, patient tolerance, and whether the patient has contraindications to one or the other.
For CIDP, treatment options are broader. Corticosteroids, IVIg, and plasma exchange all have evidence supporting their use. A Cochrane review of corticosteroids for CIDP found that both daily oral prednisolone and monthly high-dose pulsed dexamethasone led to similar remission rates, with no clear winner between the two steroid regimens.18PubMed Central. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy Intravenous methylprednisolone (a steroid given through an IV) has also been studied head-to-head with IVIg and oral immunosuppression. In one comparison, both IV steroids and IVIg produced meaningful strength gains over six months, with most patients in both groups improving, while a smaller proportion of those on oral immunosuppressive drugs alone showed improvement.19JAMA Neurology. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy With High-Dose Intermittent Intravenous Methylprednisolone The clinical reality for many CIDP patients is that they need ongoing maintenance therapy, sometimes rotating between treatments as their response changes over time.
For metabolic causes, the priority is controlling the underlying condition. Tightening blood sugar control in diabetes slows the progression of diabetic neuropathy, and correcting a vitamin deficiency can sometimes reverse nerve damage if caught early enough. In toxic neuropathies, removing the offending agent, whether that means stopping a chemotherapy drug, cutting out alcohol, or eliminating an occupational exposure, is the essential first step.
Managing Neuropathic Pain
Pain control is often the most pressing concern for patients, regardless of the underlying cause. Neuropathic pain does not respond well to ordinary painkillers like ibuprofen or acetaminophen. Instead, several classes of medications originally developed for other conditions have become the mainstays of treatment.
Gabapentinoids (gabapentin and pregabalin) and certain antidepressants (duloxetine and tricyclics like amitriptyline) are the most widely prescribed. In diabetic peripheral neuropathy specifically, a meta-analysis comparing duloxetine and gabapentin found no significant difference in overall pain relief or patient-reported global improvement between the two drugs. Duloxetine did show better sleep-interference scores and a lower overall rate of side effects, though it caused more nausea and dry mouth.20PubMed Central. Comparison of the Efficacy and Safety of Duloxetine and Gabapentin in Diabetic Peripheral Neuropathic Pain: A Meta-Analysis A smaller direct comparison confirmed similar pain reduction and global impression scores between the two, with common side effects in both groups including dizziness, somnolence, and constipation.21IP International Journal of Comprehensive and Advanced Pharmacology. Safety and efficacy of duloxetine versus gabapentin in painful diabetic polyneuropathy
One finding that often surprises patients is that combination therapy may work better than any single drug. A prospective study of neuropathic pain management in various polyneuropathy types found that the estimated number of patients needed to treat to achieve meaningful relief was similar across individual oral medications, but results trended toward greater effectiveness when medications were combined.22PubMed. A prospective identification of neuropathic pain in specific chronic polyneuropathy syndromes and response to pharmacological therapy Topical agents like lidocaine patches and capsaicin cream can be added for localized pain with fewer systemic side effects. For pain that remains refractory to medication, referral to a pain specialist who can offer nerve blocks, spinal cord stimulation, or other interventional approaches is sometimes necessary.
The Role of Rehabilitation
Medications treat the disease and its pain, but physical rehabilitation addresses the functional consequences: balance problems, falls, difficulty walking, and loss of hand dexterity. Structured exercise programs that combine balance training, resistance exercises, and aerobic conditioning can improve walking stability, muscle strength, and overall quality of life for people with polyneuropathy.23PubMed Central. The Role of Physical Exercise and Rehabilitative Implications in the Process of Nerve Repair in Peripheral Neuropathies: A Systematic Review Occupational therapy helps with fine motor tasks that become difficult when hand sensation or grip strength declines, from buttoning a shirt to using a keyboard.
Foot care is a practical concern that gets too little attention. When sensation in the feet is diminished, small injuries like blisters, cuts, or pressure sores can go unnoticed and develop into serious infections. Daily foot inspections, properly fitted shoes, and regular podiatric checkups prevent a disproportionate share of the complications that send neuropathy patients to the hospital.
Polyneuritis in Children
Although polyneuropathy is far more common in adults, children are not immune. In pediatric populations, the list of causes shifts: inherited neuropathies (like Charcot-Marie-Tooth disease) become more prominent, while metabolic causes like diabetes-related neuropathy appear in the context of type 1 disease rather than the type 2 that dominates in adults. Systemic conditions such as critical illness, chronic kidney failure, vitamin deficiency, certain cancers, sickle cell disease, and connective tissue disorders can all produce secondary neuropathy in children.24PubMed Central. Peripheral nerve disease secondary to systemic conditions in children Management in children focuses heavily on symptomatic care, pain control, and rehabilitation, though some neuropathies improve when the underlying condition is brought under control. Because children are still growing and developing motor skills, early physical and occupational therapy is particularly important to prevent long-term functional limitations.
Why So Many Cases Go Unexplained
Even after a thorough workup, roughly a quarter to a third of polyneuropathy cases end up without a definitive cause. These are labeled “idiopathic” or “cryptogenic” polyneuropathy. The frustration for patients is real: you have clear symptoms and abnormal nerve-study results, but no identifiable reason. Most idiopathic cases are slowly progressive, predominantly sensory, and follow the stocking-glove pattern. Some experts suspect that many of these reflect undetected prediabetes, subclinical autoimmune processes, or genetic variants that current testing does not catch. As diagnostic tools improve, including antibody panels that were unavailable a decade ago and more sensitive genetic testing, the proportion of truly unexplained cases is gradually shrinking. For patients in this category, treatment is symptom-focused: managing pain, maintaining function through exercise, and monitoring for any change in the clinical picture that might point toward a specific diagnosis over time.